Denovai
Dynamic protein design
DenovAI aims to rapidly accelerate drug discovery by developing a novel, AI-based platform that can design high affinity therapeutic antibody and miniprotein binders for protein targets of choice, completely from scratch.
Promise Bio
Deep cellular insights
Promise Bio is developing the first platform that performs unbiased, broad-range epiproteomic analysis for precision medicine in complex chronic conditions, including autoimmune diseases. Our cloud-based platform delivers timely, clinically valuable insights to enable treatment personalization and response predictions.
tenAces
Molecular glue discovery
TenAces Biosciences aims to improve patients’ lives by developing rationally designed molecular glue therapeutics for enhanced targeted protein degradation. Using a data centric approach and machine learning, TenAces is able to study the various interactions, protein pairs, and multi-dimensional features to predict new molecular glues.
Combinable
Tailored antibody optimization
Combinable addresses a key challenge of trial-and-error in pharma development and manufacturing, by developing an in silico solution that optimizes properties concurrently. This approach seeks to identify multiple drug candidates that achieve a balanced profile across diverse characteristics, thus expediting and refining the drug discovery process.
Omec
Deep cellular insights
Omec.AI aims to improve the probability of success of drug candidates in clinical trials by analyzing pre-clinical safety and efficacy data. OMEC.AI builds a next-generation computational platform that can identify hidden safety liabilities and lack of efficacy for drug candidates, and suggest experiments to close the identified gaps.
ProPhet
Small molecules. Large scale.
ProPhet uses state-of-the-art #MachineLearning technologies, including diffusion models and large language models, to identify active small molecules for #DrugDiscovery.
Past Challenges
Call for Applications: Entrepreneur in Residence for New Venture Leveraging AI for Clinical Trial Control Arms
AI/ML Platform for Targeting RNA With Small Molecules challenge
Identification of Active Small Molecules for Drug Discovery challenge
AI Powered Discovery to Enable Molecular Glue Therapies challenge
Prediction of clinical trial outcome in biomarker stratified cancer patient populations challenge
Artificial Intelligence for Design and Optimization of Antibodies for Targeted Therapies challenge
Artificial Intelligence to Predict Clinical Trial Readiness of Drug Candidates challenge
